Despite the inclusion of an older population in the current study, one cannot preclude a potential breast cancer protective effect of denosumab (or other RANKL inhibitors) in younger high-risk populations, particularly among women with an inherited BRCA1 mutation. The gene discussed is BRCA1; the disease is breast cancer.